Barzolvolimab Post-Treatment Durability —Off-Treatment Data, Complete Response Rates, and Quality-of-Life Outcomes

Among the most clinically striking findings to emerge from recent urticaria research is evidence that therapeutic benefit in CSU may persist substantially beyond the cessation of active treatment — a pattern observed in a phase 2 exploratory analysis of barzolvolimab, an anti-KIT monoclonal antibody targeting the mast cell stem cell factor receptor, presented at the 2026 American Academy of Allergy, Asthma & Immunology meeting. The analysis examined patients who completed 52 weeks of barzolvolimab — at doses of either 150 mg every 4 weeks or 300 mg every 8 weeks — and achieved at least well-controlled disease, defined as a UAS7 of 6 or less, at week 52. Of 55 qualifying patients, 48 had data available at week 76. At study entry, 71% of this subgroup had severe disease and the mean UAS7 was 31.5 at baseline — a substantially burdened population. By week 52, 87% had achieved a complete response (UAS7 = 0) and 13% had well-controlled disease.

The off-treatment follow-up data are notable on multiple levels. At week 76 — 28 weeks after the final dose — 50% of patients maintained a complete response and 19% maintained well-controlled disease, with approximately 69% maintaining at least well-controlled disease without any ongoing therapy. Among those sustaining complete response at week 76, the mean UAS7 was 0.4, the mean Dermatology Life Quality Index (DLQI) was 1.17, and 83% had a DLQI of 0 or 1, indicating no meaningful impact of disease on quality of life. This off-treatment durability was observed despite confirmed clearance of barzolvolimab from circulation and normalization of serum tryptase — a mast cell biomarker — findings the study authors characterize as consistent with disease modification rather than symptom suppression alone, and which provide the scientific basis for the agent's ongoing phase 3 development.

In this segment of the video discussion on CSU management updates, Steve Dorman, MD, walks through the week 76 findings in detail, emphasizing that the persistence of complete response nearly 7 months after the last dose — in a population that entered the study with severe, long-standing disease — is not a pattern previously observed with any other agent in the CSU therapeutic landscape. The normalization of serum tryptase alongside the clearance of drug from circulation is a particularly important mechanistic signal, as it suggests that the disease-modifying effect is not dependent on ongoing drug exposure. Eric Karlin, MD, frames the DLQI outcomes as the patient-centered complement to the activity scores: an 83% rate of DLQI 0 or 1 at week 76 in patients who are no longer on therapy describes a population that has, by their own report, effectively returned to normal life.